Valneva: Lyme Disease Vaccine, Phase 3 Results Expected with Pfizer
Valneva has announced the participation of its management in three investor conferences in the United States and Europe over the next six weeks. Thomas Lingelbach, CEO, and Peter Bühler, CFO, will present value creation elements and expected catalysts of the group specialized in vaccines.
Valneva's Upcoming Investor Presentations
Valneva will hold presentations and meetings with institutional investors at three events: the 46th annual TD Cowen Health Care Conference in Boston on March 4th, the Jefferies 2026 Biotech on the Beach Summit in Miami on March 10th, and the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15th. On these occasions, the management will present the main catalysts of the group, including the first Phase 3 results for VLA15, the Lyme disease vaccine candidate developed in partnership with Pfizer, expected in the first half of 2026.
Live Broadcast and Replay of the Presentation
The presentation on March 4th in Boston will be broadcast live and available for replay on Valneva's investor website. Institutional investors interested in meeting the company during these conferences are invited to contact a representative of the concerned banks.
